News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Navigating the Recession and Patent Expirations

July 6, 2023
By Arda Ural, PhD
Publication
Article
Pharmaceutical ExecutivePharmaceutical Executive: July 2023
Volume 43
Issue 7

Pharma is built to overcome, but focus on fundamentals remains key.

Arda Ural, PhD

Arda Ural, PhD
EY Americas Industry
Markets Leader
Health Sciences and Wellness

The perennial nature of life sciences protects the sector from adverse macroeconomic conditions. We have tested this hypothesis by examining 40 years of trends, learning that downturns have a limited impact on growth.

But now, will the current economic environment, with a potential recession looming, challenge this resilience? Further, can the biopharmaceutical industry weather the storm caused by a massive wave of patent expirations of biologics assets?

Steady growth amid the headwinds

Even if inflation limits consumer spending, the number of dispensed prescriptions has shown an annual increase of 3.4% from 1992 to 2021, according to IQVIA. This is due to an aging population, more diagnoses, and new therapeutics, leading to a perpetual demand for pharma products. Additionally, Congressional Budget Office data shows that the average cost per prescription remained flat or declined slightly in the last 10 years, explained by pricing pressures and increased use of generics.

A key measure of resiliency is continued R&D spend and the number of clinical trials in Phases I–III, and both measures have increased in recent years. In fact, according to an analysis of data at ClinicalTrials.gov and Capital IQ, the number of clinical trials has increased 191% since 2012, and R&D as a percent of sales is up 15% over the same period. This indicates that the biopharma research engine is unaffected by recent downturns.

Further, this focus on innovation has helped lead to an increase in FDA approvals of both new molecular entities (NMEs) and biologics license applications (BLAs), which reached a median of 41 per year from 2010 to 2021 vs. 26 per year in the previous decade. The dot-com bubble burst saw a slight rise in approvals, up to 29, and stayed relatively consistent through the 2008 financial crisis (25 approvals). During the first major wave of COVID-19 in 2020, an unprecedented 53 NMEs were approved.

Additionally, according to data from the Bureau of Labor Statistics and the Pharmaceutical Research and Manufacturers of America (PhRMA), the life sciences workforce has grown at a faster rate than the overall US labor force over the past 15 years: 1.5% CAGR vs 0.6% CAGR, reaching 1.14 million in 2022. The only slight dip was from 2008 through 2011—the period of the notorious $100 billion small-molecule patent cliff.

Patent cliff to test industry resilience

While the industry has shown resiliency, it currently faces major challenges: inflationary pressures on out-of-pocket prescription spending; increased cost of capital; near-shoring of the supply chain; and tight margins from rising labor costs. On the top end, revenue is being squeezed by the Inflation Reduction Act and the patent cliff, estimated by Evaluate Pharma at $226 billion in lost global prescription sales through 2026.

Still, the industry cannot afford to dial back on R&D. For companies with a strong balance sheet and cash flow, a downturn may facilitate acquisitions for growing therapeutic areas. In the January 2023 EY CEO Outlook global survey, 47 life sciences CEOs said cost reduction to maintain profitability would be an important near-term priority.1 When investing, firms are prioritizing digital transformation, resilience, sustainability, and operational efficiencies, aiming to exit the downturn stronger than their competitors.

At the same time, the industry should address its long-overlooked cost base. Over the last decade, according to CapIQ and EY analysis, the selling, general, and administrative expenses (SG&A) level has remained steady at around 28.8% of revenue. Today’s intelligent automation and outsourcing capabilities are on full display in other industries, and while biopharma is a pioneer in innovation, its adoption of digital tools has lagged. Automation of back-office processes and using shared services can lower SG&A spend and, in turn, reduce costs, allowing companies to fund continued innovation.

For life sciences companies, the economic environment is among the most challenging in decades, and the impending patent cliff will be difficult to overcome. However, biopharma has historically proven to be resilient to macro challenges and recovered from its first patent cliff with a surge in innovation. Focusing on fundamentals, such as new therapeutic modalities, acquiring novel technologies, and using automation, artificial intelligence, and machine learning to lower its cost base, will help the industry navigate the path ahead.

References

  1. EY. CEO Survey: US CEOs Brace for a Recession of Unknown Magnitude, Jan 12, 2023, https://www.ey.com/en_us/ceo/ceo-survey-us-report

Download Issue PDF
Articles in this issue

Pharm Exec roundtable
The AI Revolution Has Arrived: Shaping the Next Generation of Pharma Marketing
Kabir Nath
Crossing the Brain Barrier
Matthew Arnold
Biotech’s Survival Story: Companies Bear Down for Lean Years
Celeste Warren
DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles
Doron Aspitz
Harnessing AI for Pharma Sales
Bruce Liu
Tapping New and Improved Drug Innovations in Asia
Jill Wechsler
Drug Shortages Continue to Plague FDA, Manufacturers
EU flag
Contrasting Aims Highlight Pharma Reform Pursuits
Barabara Ryan
Shifting Macro Trends Offer Hope for Biotech Performance Boost
Ira Studin, PhD
‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk
Arda Ural, PhD
Navigating the Recession and Patent Expirations
Meg Rivers
Marketing in the AI Age
Mike Hennessy Jr
AI Heating Up On the Pharma Stage
Pharm Exec July 2023
Pharmaceutical Executive, July 2023 Issue (PDF)
Recent Videos
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Related Content

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

Don Tracy, Associate Editor
May 20th 2025
Article

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.


Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.


FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

Don Tracy, Associate Editor
May 15th 2025
Article

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age.


Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.


Stock.adobe.com

NAMI Responds to Potential Cuts to Medicaid

Mike Hollan
May 15th 2025
Article

The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses.


FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

Don Tracy, Associate Editor
May 14th 2025
Article

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine.

Related Content

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

Don Tracy, Associate Editor
May 20th 2025
Article

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.


Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.


FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

Don Tracy, Associate Editor
May 15th 2025
Article

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age.


Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.


Stock.adobe.com

NAMI Responds to Potential Cuts to Medicaid

Mike Hollan
May 15th 2025
Article

The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses.


FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

Don Tracy, Associate Editor
May 14th 2025
Article

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.